

Ocaliva® (obeticholic acid) - Safety update

- On May 26, 2021, the <u>FDA announced</u> that a new *Contraindication* will be added to the <u>Ocaliva</u> (<u>obeticholic acid</u>) drug label stating that it should not be used in primary biliary cholangitis (PBC) patients with advanced cirrhosis.
 - The Boxed Warning will also be revised to include this information along with related warnings about this risk.
- PBC is a rare, chronic disease affecting the ducts in the liver that carry bile, which helps with digestion.
 Some PBC patients with cirrhosis who took Ocaliva, especially those with evidence of advanced cirrhosis, developed liver failure, sometimes requiring liver transplant.
- Ocaliva was approved in May 2016 and is indicated for the treatment of PBC in combination with <u>Ursodiol® (ursodeoxycholic acid)</u> (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. The benefits of Ocaliva continue to outweigh the risks for its FDA approved indication.
- Patients with PBC who have cirrhosis and are taking Ocaliva should talk to their health care provider about these new warnings.
- Patients should immediately contact their health care provider if they develop signs or symptoms of
 worsening liver injury or development of advanced cirrhosis such as swollen/painful belly, yellowing of
 the eyes or skin, bloody/black stools, coughing or vomiting blood, metal status changes, nausea
 vomiting or diarrhea, loss of appetite, fever, tiredness, and less frequent urination.
- Before initiating Ocaliva, health care providers should determine whether a patient with PBC has
 advanced cirrhosis as the medicine is contraindicated in these patients. Patients should be routinely
 monitored for progression of PBC with laboratory and clinical assessments, and clinically significant
 adverse effects, to determine whether the medicine needs to be discontinued. Ocaliva should be
 permanently discontinued in patients with cirrhosis who progress to advanced cirrhosis.
- The safety update is based on information submitted to the FDA Adverse Event Reporting System and the medical literature.
 - In the five years since Ocaliva's approval, there were 25 cases of serious liver injury leading to liver decompensation or liver failure associated with Ocaliva in PBC patients with compensated or decompensated cirrhosis.
 - Many patients had advanced cirrhosis before starting Ocaliva and all were taking Ocaliva at recommended dosages.
 - After starting Ocaliva, the pace of the liver decompensation or failure reported suggested these adverse events, which resulted in liver transplant in a small number of cases, were related to the drug rather than progression of the underlying PBC.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.